{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"73.800","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"372,671,212","primaryexch":"HKEX","ric":"6855.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BK9PZW2","am":"165.51","iv":"","ew_strike":"","as":"72.700","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"72.350","registrar":"Tricor Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-26 10:38:37.0","lo52":"31.350","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Yang Dajun","underlying_ric":"6855.HK","hi52":"95.350","issuer_name":"Ascentage Pharma Group International - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"71.750","mkt_cap":"27.09","f_aum_hkd":null,"ew_sub_per_to":"","ls":"72.700","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-1.800","aum":"","issued_shares_class_B":null,"vo":"2.28","secondary_listing_flag":false,"listing_date":"28 Oct 2019","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Ascentage Pharma Group International - B","nm_s":"ASCENTAGE-B","sym":"6855","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.","op":"72.900","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Unit B, 17/F<br/>United Centre<br/>95 Queensway<br/>Admiralty, Hong Kong","pc":"-2.42","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"74.500","isin":"KYG0519B1023","moneyness":""}},"qid":"1758890099327"}
